We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
In a setback for generics makers, AstraZeneca prevailed in a patent-infringement lawsuit when a federal judge validated the company’s patent for the diabetes drug Onglyza. Read More
Aspen Pharma and Deco Pharma, the company’s distributor, face disciplinary proceedings from Spain’s antitrust authority for allegedly limiting the distribution and hiking the prices of drugs. Read More
A lawsuit filed by the state of California alleges several drug manufacturers made a “pay-for-delay” deal to keep generic competition off the market. Read More
The FTC is asking a Georgia federal court to remove Par Pharmaceuticals and Paddock Laboratories from an antitrust case that alleges the companies delayed the market entry of their AndroGel generics in exchange for payments. Read More
The federal government issued a subpoena to Biogen requesting information on prices, rebates and co-assistance programs for four of its therapies, according to an SEC filing by the company. Read More
PhRMA is urging the USPTO to reevaluate patent eligibility for prescription drugs to provide the drug industry a better framework for interpreting regulations and recent case law. Read More